Vaxart, Inc. (VXRT) Earnings Call Transcript & Summary
March 14, 2024
Earnings Call Speaker Segments
Edward Berg
executiveHello everyone, and welcome to the call this afternoon. Representing Vaxart today are Dr. Michael Finney, our Interim Chief Executive Officer; Dr. Sean Tucker, SVP and Chief Scientific Officer; Dr. James Cummings, Chief Medical Officer; and Phil Lee, Chief Financial Officer. Ahead of diving in, please note that during this conference call, Vaxart might issue forward-looking statements. These cover the company's financial results, financial guidance, future business strategies and operations, along with product development and regulatory progress — including remarks about clinical trials that are underway or planned. Several significant elements might lead real outcomes to diverge substantially from what these forward-looking statements describe, among them the unpredictability that is intrinsic to clinical development and the regulatory process, plus additional risks outlined within the Risk Factors portion of Vaxart's latest Annual Report on Form 10-K, as well as in other periodic filings made with the SEC. Vaxart assumes no duty to revise any forward-looking statements following the date of this call. At this point I'll hand the call over to Dr. Michael Finney. Mike?
Michael Finney
executiveThank you, Ed, and I appreciate everyone being here today; it's great to speak with all of you during such an exciting point in this company's evolution. Since this marks my first quarterly call alongside you, I'd like to open with a short introduction about myself and what I've observed about our organization, after which I'll hand things over to the rest of the team so they can walk through what we've recently achieved, our clinical programs, the milestones we have planned ahead, and how we performed across the full year. To start, this is my second stint as Vaxart's CEO, after holding a comparable role from 2009 to 2011. I've sat on the Vaxart Board since 2007 and have chaired that Board since March 2023. Over my years with Vaxart, I've watched this company pass through numerous stretches of clinical and corporate expansion while taking on all sorts of fresh challenges. My confidence in this team and where we're headed has never been higher than it is at this moment. I strongly believe that 2023 represented a transformative year for this business and for our mucosal technology; we achieved meaningful headway on our oral vaccine platform, finishing 2 Phase 2 clinical studies covering our norovirus oral vaccine candidates, and we've now built proof of concept across 2 challenge studies spanning both respiratory and GI viruses. Considering everything the data has shown us through these trials and the others we've reported, I believe it's evident what we're holding in our hands. Our oral pill vaccines carry a genuinely strong prospect of delivering multiple benefits over injectables, such as the capacity to immunize individuals more quickly, more easily, and without pain, with no requirement for cold chain storage or trained medical professionals to give the vaccine, plus the potential for mucosal immune response; we've already established through preclinical and clinical trials that our candidates possess a favorable immune profile, bring about serum antibody and serum neutralizing antibody responses, generate potent T cell responses, produce mucosal immune responses, and are capable of inhibiting virus shedding, which could affect how the virus transmits. Considering where the field stands today, and especially in light of the BARDA contract we were recently awarded, we're now positioned to take a significant leap forward with our COVID-19 program. James will cover the specifics of the preparation and the study design, but it's obvious that the federal government recognizes the need for improved vaccines that leverage mucosal immunity's power to fight the current STD and any future variants of this virus more effectively. That first generation of vaccines was a beginning, yet these viruses keep evolving. There's far more we can accomplish, and Vaxart stands ready to take on that challenge and prove what our technology can do. Meanwhile, we continue making consistent headway on our norovirus program. We've finished analyzing the data from the recent challenge study and have pinpointed a possible correlate of protection, which will shape the upcoming meeting we have with the FDA to talk over the best path ahead for this program. We still think our norovirus vaccine candidate is the furthest along in clinical development compared to others, and it is made to be taken by mouth and intended to reach the gastrointestinal tract. In the U.S. and around the world, norovirus imposes an enormous economic toll, and we are eager to develop an oral vaccine that reduces that toll for millions of the most vulnerable people in society. Last, it is my great pleasure to share that we revealed the hiring of a permanent President and Chief Executive Officer, Steve Lo, last week. Steve carries extensive biopharma knowledge to Vaxart, with over 25 years spent in healthcare, biotech, and pharmaceuticals, among which over 12 years were in the C-suite. He has concentrated especially on development and commercialization, and he assisted two companies in launching their first product. Vaxart is positioned exceptionally well to move its mission forward. We are delighted to bring in a highly capable, seasoned CEO to lift this company to new heights and generate value for our shareholders; and at present, I will step down as CEO while keeping my role as Chair of the Board. Steve starts at Vaxart on March 18, and we are delighted to have him join. I will now hand the call to James so he can go over recent developments in our coronavirus program.
James Cummings
executiveThank you, Mike. To begin, I'd like to express gratitude to the members of our clinical, regulatory, CMC, and research groups, whose relentless efforts across almost 4 years have driven our COVID-19 program. Without their persistence and commitment to our innovative science, the recent advances this program has achieved would not have been possible. In January, everyone at Vaxart felt a real boost when BARDA awarded us a contract worth $9.27 million, intended to get us ready for a 10,000-subject Phase 2b clinical trial. That study will test our company's oral pill XBB COVID-19 vaccine candidate head-to-head with an approved mRNA vaccine comparator. The award forms part of Project NextGen, the federal government's initiative aimed at strengthening our country's pandemic preparedness and enhancing how we collectively fight COVID-19. To date, only a small number of companies have secured BARDA funding to prepare for a Phase 2b clinical trial under this highly significant initiative, and Vaxart is among them. The government's backing gives us confidence, and we see it as a sign of the promise held by our differentiated strategy for addressing COVID-19, which remains an ongoing challenge. With this support, Vaxart will be able to advance our oral COVID-19 program. At present, we are busy getting ready to launch this Phase 2b trial, which could begin as soon as Q2 of 2024. The design calls for a Phase 2b, double-blinded, multi-center, randomized, comparator-controlled clinical trial assessing the relative efficacy, safety, and immunogenicity of Vaxart's investigational oral SARS-CoV-2 XBB vaccine tablet versus a currently approved mRNA COVID-19 needle-injected booster vaccine in adults who have previously been immunized against COVID-19 infection. While these clinical trial preparations proceed, we are pursuing additional funding that would help us start and carry out the Phase 2b study. As events warrant, we'll share the timing and amount of any such additional funding. Assuming that extra funding comes through, we aim to be among the first Project NextGen recipients to kick off our Phase 2b head-to-head clinical trial. Last month, we once again highlighted the cross-protective potential of our COVID-19 vaccine candidates, with data we had previously announced appearing in the journal Vaccines. Those preclinical non-human primate findings demonstrated that our vaccine candidates were capable of protecting against several SARS-CoV-2 variants of concern, since they produced strong antigen-specific serum IGG and IGA responses with neutralizing activity. In addition, vaccination lowered SARS-CoV-2 shedding after infectious challenge in the upper and lower airway of non-human primates. Being published in highly respected journals like Vaccines matters a great deal, because it keeps demonstrating that the scientific community recognizes our pioneering research. Such data additionally act as the basis for our present COVID-19 vaccine candidates, which the forthcoming Phase 2b clinical trial will evaluate. Vaxart's broad platform and technology hold enormous promise. In our view, this platform might reshape the landscape not just for COVID-19 vaccines, but for other infectious diseases posing major threats to global public health, including norovirus and influenza. Our whole team makes us extremely proud as we keep leading the way in mucosal vaccine science. At this point, I'll turn the call over to Dr. I’ll turn it over to Sean Tucker, who is our Founder and Chief Science Officer, so he can give us the latest on the norovirus vaccine program. Sean?
Sean Tucker
executiveThanks, James. In 2023, our norovirus program moved ahead considerably, and we reported top-line results from 2 Phase 2 trials, one of which was a challenge study involving our G11 monovalent candidate. The majority of those data have now been reviewed, and we think we remain on schedule to pinpoint possible correlates of protection that can help move our bivalent norovirus candidate forward. For this vaccine candidate, and for our platform as a whole, we consider what we've reported so far to be encouraging. Near the end of Q4, we finished enrolling participants in our Phase 1 clinical trial, which is assessing whether our norovirus vaccine candidate can cause antibodies to appear in the breast milk of lactating mothers and pass those antibodies along to young infants. As a reminder, the Bill and Melinda Gates Foundation is providing partial support for this study. This Phase 1 trial is multicenter, randomized, double-blind, placebo-controlled, and dose-ranging, and it is intended to assess safety, tolerability, and immunogenicity of our orally administered bivalent G11, G24 vaccine among healthy lactating females who are 18 years of age or older. At 5 sites in South Africa, 76 subjects were enrolled. Those subjects were randomly assigned to receive either a high dose or a low dose of vaccine, or placebo. The study's primary endpoints are how often, how long, and how severely solicited symptoms occur for 1 week after the dose of study drug, along with the frequency, duration, and severity of unsolicited treatment adverse events, serious adverse events, adverse events of special interest, and new onset of clinical illness during the active period. Most exciting in particular is that this study will look for VP1-specific IgG1 and IgG4 IgA in the serum and in the breast milk; at present, we expect to announce top-line results from this Phase 1 trial in mid-2024. Looking ahead, we intend to meet with the FDA in the second quarter of 2024 to talk about our data on potential correlates, a Phase 2b dose confirmation study, and possibly a G24 challenge study; as we see it now, a Phase 2b study would produce enough safety data for an end-of-Phase 2 meeting with the FDA. Such an end-of-Phase 2 meeting would let us reach agreement with the FDA regarding the scope and design of a Phase 3 pivotal efficacy study in adults over 18 years of age. Even so, what type of clinical study comes next, and when it happens, will be settled after our Q2 meeting with the FDA; we intend to give an update on this program's next steps as soon as we can once that meeting concludes. I'll now turn the call over to Phil Lee, our CFO, for a short discussion of our financials. Phil?
Phil Lee
executiveThanks, Sean. A summary of how we did financially across the whole of 2023 can be found in the press release issued today. For 2023, revenue came in at $7.4 million, which compares with $0.1 million during 2022. Most of that 2023 revenue was recognized for work carried out under the grant Vaxart received from the Bill & Melinda Gates Foundation, along with non-cash royalty revenue tied to higher Inavir sales in Japan. As 2023 came to a close, Vaxart held cash, cash equivalents, and investments totaling $39.7 million. That cash figure excludes roughly $15 million of net proceeds that were raised in early 2024. Vaxart expects its present cash to fund operations into the fourth quarter of 2024. I appreciate everyone taking the time to join us today. We'll now begin the question-and-answer portion of the call.
Analyst
analystHello, everyone. Asia here, filling in for Charles. Our question concerns the study involving lactating mothers. Could you discuss what results from this Phase 1 trial you'd hope to observe that might set the oral norovirus apart even more with respect to the target product profile, and perhaps help secure approval down the road? Thanks.
Michael Finney
executiveSean, would you like to take that question?
Sean Tucker
executiveYeah, I'll kick things off, and then James can come in. Yeah, the crucial point with this experiment—or rather, this clinical study—is that when we administer the vaccine to mothers who are lactating, our hope is to detect antibodies in breast milk, and those antibodies present in breast milk are going to be passed along to young infants. As you probably know, one of the primary—I should say, young kids are likely the most vulnerable to norovirus infection. And by getting those antibodies into children, whether through breast milk, we believe that's going to make a big difference. Our hope is that this, not just through safeguarding the mother and the children, we might also safeguard, basically, if these antibodies turn out to be very good with great efficacy, we might also have the ability to stop transmission to other individuals in the community. James, would you like to add anything?
James Cummings
executiveAppreciate that, Sean. Maternal immunization has a long, substantial track record when it comes to protecting kids. What I find compelling, though, is that our broad platform performs so impressively on mucosal immunity as well as IGA production. So examining those concentrations in breast milk through a more rigorous approach, and then exploring how infants might fare when receiving that breast milk full of maternal antibodies, ought to significantly advance what we know about the way this platform might ultimately benefit that pediatric group.
Liang Cheng
analystThank you, that's great. Liang Cheng here, speaking for Roger Song. We've got a few questions for you. I suppose the first one would be this: could you walk us through the economics behind the BARDA NextGen funding once more, and what kind of effect would that have on your runway through the year? After that, I have a few more questions to ask. Thanks.
Michael Finney
executiveSure. Under the BARDA contract that we made public back in January, money is being provided so we can get ready for a Phase 2b COVID-19 trial. When it comes to BARDA's award process or its timing, we aren't able to speculate. There have been other companies saying they fell under an option agreement with BARDA under which BARDA could supply roughly $400 million in order to carry out the contract. Our view is that as we hit the milestones laid out in this contract, we should find ourselves able to get more funds. As for the specifics, those are simply not something we can discuss at this point. Once we have more visibility, we'll come back with an update.
Liang Cheng
analystCertainly, thanks. Then moving on, my following question concerns the protection correlates. So I'm curious — in what way might those protection correlates influence the plan for your Phase 3 study?
Michael Finney
executiveSean, that's an area where I'd say you're the one with the expertise.
Sean Tucker
executiveAlright, I'll kick things off, and once more, I'll have James come in after me. Knowing which immune measurements matter strikes me as valuable for multiple reasons. One point, though, is this: when a correlate of protection has already been established for your vaccine — meaning you know that measuring a particular immune parameter translates into protection — that could shrink the number of participants required in a Phase 3 efficacy trial. The reason is that such a correlate can basically be leveraged to figure out what counts as protective, and you can apply it to connect across age groups. James, anything you'd like to add?
James Cummings
executiveThanks, Sean. So, we're really thrilled about what Sean and his group are accomplishing in that area. And, as Sean pointed out, establishing a correlate represents quite an impressive achievement; through additional talks, there's a chance we could view that as a surrogate for protection. And like Sean said, it would affect both how many subjects are needed for a Phase 3 clinical field study, and possibly how long that study would run, since we'd be examining those immune correlate parameters rather than only field efficacy. So, we'll have more to share once we hold that discussion soon. Thank you.
Liang Cheng
analystUnderstood, thanks. Perhaps for my final question, I wanted to ask about that possible Phase 2 G24 challenge study — so what would be the main things to weigh, or the discussions to have, about whether that study is actually needed?
Michael Finney
executiveJames, could you take that one?
James Cummings
executiveSure, thanks, Roger. So I think, you know, we're going to learn quite a bit from our discussion with the agency. If they want more information from another challenge, then G24 would be a challenge study that could be run. You know, it's something we've explored as a just-in-case situation, if it's needed. And if it isn't, you know, it isn't, right? I think we'll have much more clarity on whether we're required to conduct another challenge study once we've had that meeting with the agency.
Michael Finney
executiveThanks, James.
Liang Cheng
analystUnderstood — appreciate it. That's all we have.
Michael Finney
executiveThanks.
Madison El-Saadi
analystHey there, everyone. This is Madison, filling in for Mayank. Nice work on the progress. If I could piggyback on something asked earlier: assuming you do run a G24 challenge study, how quickly do you figure you could have it underway? Then, a separate item — perhaps you said this already and I missed it, but regarding the BARDA Phase 2, are you going to rely on commercial-grade material for your <<inaudible>>?
James Cummings
executiveMike, do you want me to take that one?
Michael Finney
executiveYes. Please do.
James Cummings
executiveI certainly will. So, regarding your second question, to start with, I suppose: that phase 2b study that would be run is exactly that. It's a clinical trial conducted under the good clinical practice guidelines along with the rules and regulations set by the FDA. Therefore, it calls for GMP-manufactured material, which is what we utilize across all of our clinical trials. So, I believe that clears that up. The comparator vaccine is going to be an approved mRNA vaccine given by needle injection, and we will be comparing how effective both of those vaccines, or candidate vaccines, are relative to each other. We'll also be examining safety; on our platform, we have, thankfully, a very clean safety profile, and we'll be comparing that against the solicited and unsolicited adverse events, both from our product and from that needle-based injection of an mRNA booster. And we'll be reviewing that data too. What was your second question?
Madison El-Saadi
analystAnd second, to build on what was asked before — if, following that meeting with the FDA, it turned out that you were going to conduct a challenge study, I'm just wondering how quickly your team could get that going?
James Cummings
executiveWell, I believe it really hinges on whatever the FDA's guidance actually conveys to us, correct? So until that meeting happens, I don't want to speak on the agency's behalf or assume anything. That being said, the encouraging part is that certain groups in the United States have been working to refine that challenge model. So my sense is that we could move ahead with a challenge study in a fairly short period of time. Beyond that, I can't get any more specific until we've had the dialogue with the agency.
Madison El-Saadi
analystGot it. Thank you.
Edward Berg
executiveAppreciate it, operator. At this point we're going to take the questions our shareholders sent in; so, the opening one goes to Mike Finney. Steve Lo, who's coming in as CEO, has achieved success with first product commercialization. Did that weigh most heavily in your search? Which other qualities did you look at, and what was the process behind this pick?
Michael Finney
executiveSure, experience in both regulatory affairs and commercialization matters, obviously, but what the board wanted was someone strong across the board, and with Steve, I believe that's what we've got.
Edward Berg
executiveAppreciate that, Mike. Moving on to the following inquiry — when can we expect the next steps regarding norovirus? The focus here is on timing. After the FDA meeting you had in Q2 — and James, I believe you've already addressed part of this — but I'll direct it to you?
James Cummings
executiveAbsolutely. So the schedule and what comes next are going to hinge, like I said, on how things go in our discussions with the FDA, correct? Once that meeting happens, we'll make our evaluation at that point, and we're eager to share an update with anyone who cares to hear it afterward. What's great is that we envision a few different paths for understanding what the effect of a subsequent step might look like — perhaps involving the Phase 2b dose confirmation study to gather additional safety data, or perhaps a challenge study that could be necessary or might not be necessary, in order to supply further insight regarding correlates of protection — and beyond that, the entire notion of gazing ahead toward a possible Phase 3 study. That represents the objective.
Edward Berg
executiveAppreciate that, James. Moving on to another norovirus-related question: are you planning to share what came out of your analysis of the norovirus data, along with the correlate of protection? Sean, I believe that one falls to you.
Sean Tucker
executiveYes. I'd clearly be quite thrilled about what we've accomplished, and naturally, once we've collected its input, we'll pass our findings along to you, after which we'll evaluate what comes next for the program; when that's finished, we also intend to submit a manuscript for peer review, and once again, when that happens will be decided at a later point.
Edward Berg
executiveAppreciate that, Sean. Moving on to the next question — could you go into more detail about the work being done to get ready for the Phase 2b COVID trial? What's your expected timeline for finishing those preparations? James, I think this one falls to you.
James Cummings
executiveAbsolutely; so we've been working alongside our partners at BARDA, and I believe we've accomplished a great deal when it comes to pushing ahead and making progress on getting ready for what is truly a major undertaking, a Phase 2b trial involving 10,000 participants. As soon as that's finished, we'll give you an update.
Edward Berg
executiveAlright, thanks. That brings us to the end of the questions we have right now. So, I'd like to express my appreciation to all of you for being with us today, and with that, we're wrapping up this call. Thank you.
Michael Finney
executiveThank you, Ed.
Operator
operatorFeel free to hang up now, and I hope your day is great. Thanks for joining us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Vaxart, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Vaxart, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Vaxart, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.